Herbs & Supplements

References

Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacology and Therapeutics. 2002;27(6):391-401.

Anderson KN, Bejcek BE. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. Journal of Pharmacological Science. 2008;106(2):318-320.

Anon: Feverfew. In: DerMarderosian A, Beutler JA, eds. Facts and Comparisons: The Review of Natural Products. St. Louis, MO, Facts and Comparisons. September 1994.

Awang DVC. Feverfew Fever: A Headache for the Consumer. HerbalGram. 1993;29:34-39.

Awang DVC. Feverfew trials: the promise of--and the problem with--standardized botanical extracts. HerbalGram. 1997;41:16-18.

Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Medica. 1993;59(1):20-25.

Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. Journal of Pharmacy and Pharmacology. 1992;44:737-740.

Baumann L, Rodriguez D, Taylor SC, Wu J. Natural considerations for skin of color. Cutis. 2006 Dec;78(6 Suppl):2-19.

Cady RK, Schreiber CP, Beach ME, Hart CC. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Medical Science Monitor. 2005;11(9):PI65-P169.

Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet. 1980;2:922-923.

de Weerdt GJ, Bootsman HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. Phytomedicine. 1996;3:225-30.

Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre [sic], placebo-controlled study. Cephalalgia. 2005;25(11):1031-1041.

Eichenfield LF, Fowler JF Jr, Rigel DS, Taylor SC. Natural advances in eczema care. Cutis. 2007;80(6 Suppl):2-16.

Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health and Nutrition. 2000;3(4A):509-14.

Grieve M. Feverfew. In: A Modern Herbal. New York: Dover Publishers, 1971. Available at: http://www.botanical.com/botanical/mgmh/mgmh.html Posted 1995. Accessed October 14, 2003.

Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553-557.

Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia [sic]. Expert Opinion on Biological Therapy. 2005;5(9):1147-1152.

Haughton C. Tanacetum parthenium (L). Revised September 23, 2002. Available at: http://www.purplesage.org.uk/profiles/feverfew.htm. Accessed October 14, 2003.

HealthNotes, Inc. Feverfew. 2002. Available at: http://www.mycustompak.com/healthNotes/Herb/Feverfew.htm Accessed October 14, 2003.

Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. American Journal of Health System Pharmacy. 2000;57(13):1221-1230.

Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Extracts of feverfew may inhibit platelet behaviour [sic] via neutralization of sulphydryl groups. Journal of Pharmacy and Pharmacology. 1987;39(6):459-465.

Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet. 1985;1:1071-1074.

Hoffmann DL. Feverfew. Herbal Materia Medica. No date given. Available at: http://www.healthy.net/asp/templates/article.asp?PageType=article&ID=1884. Accessed October 14, 2003.

Hwang DR, Wu YS, Chang CW, et al. Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorganic and Medicinal Chemistry. 2006;14(1):83-91.

Jager AK, Gauguin B, Adsersen A, Gudiksen L. Screening of plants used in Danish folk medicine to treat epilepsy and convulsions. Journal of Ethnopharmacology. 2006;105(1-2):294-300.

Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. Journal of Ethnopharmacology. 1999;68:251-259.

Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.

Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Edition). 1985;291(6495):569-573.

Jordan CT. The leukemic stem cell. Best Practice and Research, Clinical Haematology [sic]. 2007;20(1):13-18.

Kemper KJ. Feverfew (Tanacetum parthenium). The Longwood Herbal Task Force. Revised November 9, 1999. Available at: http://www.mcp.edu/herbal/feverfew/feverfew.pdf Accessed October 14, 2003.

Killoran CE, Crawford GH, Pedvis-Leftick A. Two cases of compositae dermatitis exacerbated by moisturizer containing feverfew. Dermatitis. 2007;18(4):225-229.

Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chemistry and Biology. 2001;8(8):759-766.

Martin K, Sur R, Liebel F, et al. Parthenolide-depleted feverfew (Tanacetum parthenium) protects skin from UV irradiation and external aggression. Archives of Dermatology Research. 2008;300(2):69-80.

Mittra S, Datta A, Singh SK, Singh A. 5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content. Acta Pharmacol Sin. 2000;21(12):1106-1114.

Modi S, Lowder DM. Medications for migraine prophylaxis. American Family Physician. 2006;73(1):72-78.

Murphy JJ, Heptinstall S, Mitchell JR. Randomised [sic] double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189-192.

Natural Medicines Comprehensive Database, Online Edition. Pharmacist's Letter/Prescriber's Letter. Stockton CA: Therapeutic Research Facility, 2006. Available at: http://www.pharmacistsletter.com/(S(ulqz3s45omt3ag55um4kj345))/home.aspx?li=1&st=1&cs=&s=ND.

Parada-Turska J, Paduch R, Majdan M, Kandefer-Szerszen M, Rzeski W. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacology Reports. 2007;59(2):233-237.

Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis. Annals of Rheumatic Diseases. 1989;48(7):547-549.

Paulsen E, Andersen KE, Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis. 2001;45(4):197-204.

Paulsen E, Christensen LP, Andersen KE. Compositae dermatitis from airborne parthenolide. British Journal of Dermatology. 2007;156(3):510-515.

Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre [sic], randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523-532.

Pittler M, Ernst E. Feverfew for preventing migraine. Cochrane Database System Review. 2004;(1):CD002286.

Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochran Database System Review. 2000;(3):CD002286.

Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. Journal of Pharmacy and Pharmacology. 1988;40(10):743-745.

Rendon , Wu J. Enhancing sunscreens naturally. Skin & Aging. 2006;14(7):52-56.

Rios J, Passe MM. Evidenced-based use of botanicals, minerals, and vitamins in the prophylactic treatment of migraines. Journal of the American Academy of Nurse Practitioners. 2004;16(6):251-256.

Saadane A, Masters S, Didonato J, Li J, Berger M. Parthenolide inhibits I{kappa} B kinase, NF-{kappa}B activation and inflammatory response in CF cells and mice. American Journal of Respiratory Cellular and Molecular Biology. Epublished ahead of print. February 1, 2007.

Schurks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Current Treatment Options in Neurology. 2008;10(1):20-29.

Sharma VK, Sethuraman G. Parthenium dermatitis. Dermatitis. 2007;18(4):183-190.

Shrivastava R, Pechadre JC, John GW. Tanacetum parthenum [sic] and Salix alba (Mig-RL) combination in migraine prophylaxis. Clinical Drug Investigation. 2006;26(5):287-296.

Smolinski AT, Pestka JJ. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. Journal of Inflammation (London). 2005;2:6.

Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochemistry and Pharmacology. 1992;43(11):2313-2320.

Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia. 2005;25(8):612-621.

Taylor SC, Wu J. Natural ingredients in dermatology. Skin & Aging. 2005;13(7):56-62.

Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrobial Agents and Chemotherapy. 2005 Jan;49(1):176-82.

Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18(10):704-708.

Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry. 1999;51:417-423.

Won YK, Ong CN, Shen HM. Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways. Carcinogenesis. 2005;26(12):2149-2156.

Won YK, Ong CN, Shi XL, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. E-published ahead of print. March 19, 2004.

Wong HC. Is feverfew a pharmacologic agent? Canadian Medical Association Journal. 1999;160(1):21-22.

Wu J. Treatment of rosacea with herbal ingredients. Journal of Drugs in Dermatology. 2006;5(1):29-32.

Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew. Is a full reproductive study warranted? Reproductive Toxicology. Epublished ahead of print June 14, 2006.

Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics. 2005;4(4):587-594.

Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Letters. 2007;254(1):119-127.

Last Revised April 11, 2008